1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola

from Plenary Session - inactive due to federal service · host Plenary Session

In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

What this episode covers

NOW PLAYING

0:00 1:02:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 1 hour and 2 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on September 11, 2018.

What is this episode about?

Can I download this Plenary Session - inactive due to federal service episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!